Identification of somatic mutations in tumors and the development of agents that target specific affected pathways have transformed molecular diagnostics and cancer therapy. Some of the most frequently reported mutated genes in solid tumors serve as therapeutic drug targets and include EGFR, BRAF, PIK3CA, KRAS, and NRAS. [1] [2] [3] [4] [5] [6] [7] [8] Identification of a specific mutation paired with the proper targeted therapy has shown to improve the outcome of patients with some types of solid tumor, including non-small cell lung cancer, gastrointestinal stromal tumor, colorectal carcinoma, and melanoma. 2, 3, [9] [10] [11] [12] [13] [14] [15] [16] In addition to primary lesions, mutation detection also aids in the selection of therapy for metastases and recurrent tumors. [17] [18] [19] The list of genes with mutationspecific therapeutic agents is expanding. In addition, currently designed clinical trials include genomic rather than purely morphologic-based selection of candidates, thereby placing a significant emphasis on efficient screening for mutations. 1 With these changes, there is an increasing need for technologies that can provide timely mutation analysis of multiple genes using relatively small amounts of tissue.
Traditional mutation analysis techniques either provide direct evidence of mutation by using sequencing techniques, such as Sanger sequencing and pyrosequencing, or imply the presence of a mutation by using sequence-specific probes/ primers (TaqMan probes [Life Technologies, Grand Island, NY], allele-specific polymerase chain reaction [PCR] ) or identifying altered properties of a mutated sequence (highperformance liquid chromatography, capillary electrophoresis, high-resolution melting curve analysis). [20] [21] [22] [23] [24] These techniques share a common limitation of a relatively high sample requirement and low multiplexing capability. Techniques such as allele-specific PCR and TaqMan probes can achieve high analytical sensitivity but are limited to the detection of only point mutations and can be restricted in the number of point mutations that can be interrogated simultaneously. On the other hand, Sanger sequencing, widely accepted as a gold standard in sequencing, can detect insertion or deletions in addition to the point mutations over a wider range of gene sequence but is limited by its labor-intensive nature, low sensitivity, and low throughput.
The recent advent of affordable bench-top next-generation sequencing (NGS) platforms and primer extensionbased MALDI-TOF assays (PE-MALDI) allows sensitive multiplexed mutation screening and quantitative assessment of mutant allele frequency using relatively smaller amounts of tissue. MALDI specifically refers to matrix-assisted laser desorption ionization, and TOF refers to time of flight. Pairing the two processes, MALDI-TOF allows for nucleic acid detection by sample ionization followed by measuring the time required for these ionized molecules to travel through a vacuum. An excellent review of the MALDI-TOF process applied to nucleic acid and mutation detection was recently published by Van den Boom et al. 25 Both MALDI-TOF and NGS technologies are increasingly being adopted into routine clinical molecular diagnostic testing. Whereas mutation results historically have been reported qualitatively, the capability of newer test platforms allows a reproducible quantitative assessment of the mutant allele and therefore offers the added advantage of determining gene mutation burden in a tested tumor sample. The knowledge of mutant allele burden/frequency in a tumor may provide critical insights into tumor biology and serve as an important correlation point for the outcome of targeted therapy. To our knowledge, a direct comparison of the quantitative ability of NGS and PE-MALDI platforms has not been performed.
In this study, we assessed the quantitative capability of a highly multiplexed semiconductor-based NGS platform and compared the results with a PE-MALDI mutation detection platform with limited multiplexing. In addition, we correlated NGS-based mutant allele burden determination with morphologic assessment of tumor percentage for a more direct practical application of the information generated.
Materials and Methods

Study Design
The study cohort consisted of 46 patient samples with a combined total of 61 somatic mutations (somatic mutation status based on inclusion in the COSMIC database [http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/]) as identified using a quantitative PE-MALDI assay. Mutant allele burden was determined for commonly mutated genes (BRAF, KRAS, NRAS, MET, and PIK3CA), and the results were used for the correlation studies. Tumor types included melanoma (n = 23), adenocarcinoma (n = 16), papillary thyroid carcinoma (n = 4), and serous carcinoma (n = 3).
Morphologic Assessment
Morphologic assessment of tumor percentage was performed using 5-µm formalin-fixed, paraffin-embedded (FFPE) tissue sections stained with H&E. All H&E slides were reviewed by two pathologists (B.P.P. and R.K.-S.). By consensus, an area of tumor was delineated and a tumor percentage was determined as follows: percentage of tumor nuclei divided by percentage of total nuclei within the delineated tumor area. Conflicts in tumor percentage of more than 10% were resolved by external blinded review by a third pathologist (K.P.P.). Only samples with 20% or more tumor in the circled high-density tumor area were included in the study.
Sample Preparation
Sample tissue included core-needle biopsy specimens (n = 6), skin ellipses (n = 6), and excisional biopsy specimens (n = 34). DNA was isolated from FFPE tissue from solid tumors following manual microdissection of the delineated tumor area using an extraction protocol described previously. 26 Briefly, all unstained slides were cut at a 5-µm thickness from FFPE blocks; one slide was used for H&E, and five to 10 slides were utilized for DNA extraction. The unstained slides were microdissected, guided by the location of the tumor identified by review of the H&E-stained tissue section. DNA extraction was performed using a PicoPure DNA Extraction Kit (Life Technologies), following the manufacturer's instructions, after microdissection.
PE-MALDI Mutation Analysis
Quantitative PE-MALDI interrogated a total of 81 hotspot mutations in 11 genes, including AKT-1, BRAF, GNAQ, GNAS, IDH1, IDH2, KRAS, MET, NRAS, PIK3CA, and RET. Mutation detection was carried out using a ninewell-based 11-gene mutation hotspot screen developed by our laboratory using the Massarray platform (Sequenom, San Diego, CA). Briefly, DNA was PCR amplified and subjected to single-base PE using the iPLEX Gold kit and analyzed on a MALDI-TOF mass spectrometer (both from Sequenom). The regions of interest were PCR amplified using 10 ng of DNA per well. Subsequently, PCR products were treated with shrimp alkaline phosphatase to dephosphorylate unincorporated nucleotides followed by locus-specific single-base extension with mass modified dideoxynucleotides. Primers for both PCR amplification and single-base extension were designed by using the Sequenom MassAR-RAY Designer software and obtained from Integrated DNA Technologies (Coralville, IA). The mass of the products of single-base extension was analyzed by MALDI-TOF for single-nucleotide polymorphism detection. Automated mutation calls were generated using the Typer 4.0 software package (Sequenom). All automated calls were verified by manual review by a pathologist (B.P.P. or K.P.P.). Cases with discrepant results between PE-MALDI and NGS were reexamined by manual peak inspection, and a mutation call was generated based on consensus between two pathologists (B.P.P. and K.P.P.). To interrogate a mutational hotspot at codon 17 of AKT1, we added a primer pair that was designed by Life Technologies. Genomic regions to be sequenced were PCR amplified using the 191-primer pair pool. Sequencing adaptors with short stretches of index sequences (barcodes) that enable sample multiplexing were ligated to the amplicons using the Ion Xpress Barcode Adaptors Kit (Life Technologies). The library prepared was quantified using the Bioanalyzer high-sensitivity DNA chip (Agilent Technologies, Santa Clara, CA).
NGS-Based Mutation Analysis
Emulsion PCR
The library prepared for each patient sample with distinct barcoding was diluted in nuclease-free water to obtain a library stock of 160 pmol/L. From this stock, eight samples were used for a single 318 IonChip (Life Technologies). The samples were pooled and diluted further to generate a working library concentration of 16 pmol/L. To clonally amplify the library DNA onto the ion sphere particles (ISPs), we subjected the library pool to emulsion PCR (E-PCR) by following a manual method using the Ion Xpress Template Kit (Life Technologies) following the manufacturer's protocol. After manual E-PCR, the ISPs were isolated by manual breaking of the emulsion as per the manufacturer's instructions. As a measure of the efficiency of the E-PCR, estimation of the percentage of ISPs with DNA in the background of blank ISPs was performed using the Qubit ISP Quality Control Kit (Life Technologies). Enrichment of ISPs, which involves selective isolation of ISPs with clonally amplified DNA, was achieved using the Ion Torrent OneTouch ES (Life Technologies) and the IT OneTouch Kit following the manufacturer's protocol. Enriched ISPs were subjected to sequencing on a 318 IonChip to sequence pooled libraries with eight samples. Sequencing was performed using the sequencing kit (Life Technologies) as per the manufacturer's instructions. A cutoff of 300,000 reads with a quality score of AQ20 (one misaligned base per 100 bases) was used as a measure of successful sequencing of a sample. For a sequence variant to be considered, sequencing coverage of 300× and a variant frequency of at least 10% in the background of wild type (WT) were used as minimum requirements in this study. This 10% cutoff was chosen to facilitate the confirmation of mutations discovered by the Ion Torrent Personal Genome Machine (IT-PGM; Life Technologies) by alternate platforms, such as Sanger/pyrosequencing, which has an approximate 10% detection sensitivity. For the WT status, we set a minimum coverage of 250× as a cutoff.
Sensitivity Analysis
Sensitivity of the IT-PGM platform for mutation detection was determined by serially diluting DNA from H2122, a human lung carcinoma cell line with known mutations in KRAS (homozygous) and MET (heterozygous), into DNA from HL60, a human leukemia cell line. Briefly, DNA isolated from FFPE-embedded H2122 was diluted into DNA from FFPE-embedded HL60 in ratios of 1:4, 1:9, and 1:19 (H2122:HL60), resulting in 20%, 10%, and 5% dilutions, respectively. A 318 IonChip was used to assess the sensitivity of the platform to detect mutations using these diluted DNA.
Data Analysis
Alignment of sample sequence to reference genome and base calling was performed by Torrent Suite software versions 2.0.1 and 2.2 (Life Technologies). Human genome build 19 (Hg19) was used as the reference genome. Identification of variants was facilitated by IT Variant Caller Plugin version 1.0 (Life Technologies) and Integrative Genomics Viewer (IGV). 27 The IGV was used to visualize the read alignment and the presence of variants against the reference genome and confirm the veracity of variant calls by checking for possible strand biases and sequencing errors. A software custom-developed by one of the authors (M.J.R.), called OncoSeek, was used to interface the data generated by the Ion Torrent Variant Caller with IGV to visualize the alignment and mutation detected in IGV, filter repeat errors due to nucleotide homopolymer regions, compare sequencing replicates, and annotate the sequencing information. 28 
Pyrosequencing-Based Mutation Analysis
A pyrosequencing assay was designed to cover exon 15 of BRAF as described previously. 29 Briefly, to sequence exon 15 (specifically codons 595/596 and 599/600), a 231-base pair amplicon was amplified. PCR products then were confirmed via agarose gel prior to pyrosequencing. Subsequently, PCR products were analyzed via pyrosequencing using a PSQ96 HS System (Biotage AB, Uppsala, Sweden) as per the manufacturer's instructions. All assay runs included sensitivity, positive, negative, and reagent controls.
Quantitative Measurement of Mutant Allele Burden
For the NGS platform, mutant allele burden was calculated as a ratio of mutant reads to total reads for the affected base. For the PE-MALDI platform, mutant allele burden was calculated as a ratio of area under the mutant peak to the combined area under the mutant and WT peaks.
Statistical Methods
The statistical significance of the correlation was determined by the unpaired two-tailed t test. A P value less than .05 was considered statistically significant. The Spearman correlation was computed for the PE-MALDI and NGS tests. Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA).
Results
Mutation Analysis Using PE-MALDI and NGS Platforms
Manual microdissection of FFPE tumor sections was performed under a dissecting microscope to capture regions with the highest tumor content ❚Image 1A❚ and ❚Image 1B❚. Successful mutation analysis was performed on all 46 samples in parallel using both PE-MALDI ❚Figure 1A❚, which uses PCR with limited multiplexing for an 11-gene panel, and semiconductor-based NGS ❚Figure 1B❚, which utilizes highly multiplex PCR for a 46-gene panel. Pyrosequencing, which uses singleplex PCR, served as a tertiary validation method for mutant allele burden quantification and was utilized for BRAF p.V600E mutation analysis ❚Figure 1C❚. Nine of 11 genes included in the PE-MALDI panel were interrogated by the 46-gene NGS panel; the excluded genes were GNAQ and IDH2. Both platforms detected a total of 61 nonsynonymous point mutations at 100% concordance in the genes and codons covered by both platforms when mutant allele burden was 10% or more ❚Table 1❚. Gene (mutated codon, frequency) distribution of mutations was as follows: BRAF (codon 600, n = 23; codon 466, n = 1), KRAS (codon 12, n = 11; codon 13, n = 2; codon 146, n = 1), NRAS (codon 12, n = 3; codon 61, n = 8), MET (codon 375, n = 7), and PIK3CA (codon 88, n = 1; codon 542, n = 2; codon 545, n = 1; codon 1043, n = 1; codon 1047, n = 1) ( Table 1 ). In addition to the 61 nonsynonymous point mutations detected by both PE-MALDI and NGS, 16 point mutations were identified by only one of the two detection methods, three by NGS and 13 by PE-MALDI. These 16 additional mutations detected by only one platform were located in regions that were exclusive to one platform or were below the limit of detection of a platform. A detailed list of gene, mutation, mutant allele burden, and coverage depth for these 16 mutations is provided in ❚Table 2❚.
A B
❚Image 1❚ Representative H&E slide with area of tumor delineated for microdissection (A, ×10; B, ×40).
Comparison of NGS and PE-MALDI Quantification of Mutant Allele Burden
NGS-based estimation of mutant allele burden ranged from 13.6% to 79.1% for all 61 mutations. Table 1) .
The correlation between mutant allele burden detection by NGS and PE-MALDI for all interrogated mutations was r 2 = 0.79 (P < .0001) ❚Figure 2❚. The correlation between NGS and PE-MALDI was statistically significant for KRAS (n = 14, r 2 = 0.94, P < .0001), NRAS (n = 11, r 2 = 0.92, P = .0003), BRAF (n = 24, r 2 = 0.89, P < .0001), and MET (n = 7, r 2 = 0.81, P = .05). The correlation for mutations in PIK3CA (n = 5, r 2 = 0.45, P = .35) trended toward but did not reach statistical significance (Figure 2 ).
Comparison of Multiplex vs Singleplex Quantification of Mutant Allele Burden
Since both NGS and PE-MALDI involve multiplexing of PCR primers, we compared the quantitative results with a singleplex PCR method (ie, pyrosequencing) as a tertiary confirmation method for BRAF mutations. Pyrosequencing results showed a 100% concordance with both PE-MALDI and NGS for detecting p.V600E mutations ❚Table 3❚. The correlation between pyrosequencing and NGS was statistically significant (n = 18, r 2 = 0.95, P < .0001) ❚Figure 3A❚. Likewise, the correlation between pyrosequencing and PE-MALDI was statistically significant (n = 18, r 2 = 0.89, P < .0001) ❚Figure 3B❚. Therefore, the high level of multiplexing in the current NGS panel does not seem to affect the quantitative ability of this assay. Importantly, mutant allele burden for mutations involving a dinucleotide change (eg, GTG to AAG/AGG) can be calculated by NGS and PE-MALDI but not by pyrosequencing (Table 1: 
The coverage depth of sequencing for all mutations ranged from 728 to 9,958 reads per hotspot mutation (Table  1) . Average read depth in this study was 2,605 reads per 
3❚ (H&E discordant with NGS/PE-MALDI)
. In addition, analysis by specific tumor type failed to show a significant correlation between H&E-based tumor percentage and molecular test-based (NGS/PE-MALDI, pyrosequencing) mutant allele burden (data not shown).
Discussion
The arrival of bench-top NGS has launched a new era of molecular diagnostics and has opened the possibility of performing highly multiplexed gene mutation screening rapidly and with nanogram amounts of starting material. These benefits have led to the rapid adoption of NGS in the clinical diagnostics arena, where single solid tumors can have multiple mutated genes that are clinically targetable or provide prognostic information. While NGS has been rapidly adopted, the quantitative ability of NGS to determine mutant allele burden is still largely unreported. In this study, we used the well-established quantitative technique of primer extension-based PCR paired with MALDI-TOF (PE-MALDI) as a standard and evaluated the quantitative capacity of NGS. In addition, we correlated the ability of two quantitative platforms to estimate percent tumor burden and also compared these results with morphologic assessment of tumor percentage by pathologist review of H&E-stained slides.
Five commonly mutated genes in solid tumors were evaluated in this study and included KRAS, NRAS, BRAF, mutation. The level of read depth observed in this study did not seem to affect the percent mutant allele burden determined by NGS or PE-MALDI.
Correlation Between H&E-Based Tumor Percentage and Quantification of Mutant Allele Burden
Since morphologic assessment of tumor burden is an important starting point for mutation analysis and a vital correlate for interpreting mutation analysis results, we correlated H&E-based morphologic assessment of tumor percentage with NGS-based determination of mutant allele burden. The light microscopic assessment of tumor percentage in the samples tested ranged from 20% to 95% (Table  1) .35). It seems likely that the small sample population for PIK3CA mutation (n = 5) and lack of a common mutated target (five different mutations identified for PIK3CA) contributed to the lack of statistical significance in this study. Genes in this study with a number of 11 or more showed an r 2 value that was highly consistent: 0.89, 0.92, and 0.94 for BRAF, NRAS, and KRAS, respectively. This finding demonstrates that there is a strong correlation between NGS and PE-MALDI and also highlights the utility of NGS as a quantitative assay.
MET, and PIK3CA. The correlation between mutant allele burden detected by PE-MALDI and NGS was highly significant for these genes in aggregate (P < .001). These findings are consistent with a high concordance between PE-MALDI and NGS reported recently in a publication that shows the utility of NGS-based sequencing in clinical diagnostics. 30 Individually, KRAS, NRAS, MET, and BRAF showed a statistically significant correlation between PE-MALDI and NGS (P < .001). However, the correlation for PIK3CA approached but failed to reach statistical significance (P = 2). Analysis of raw NGS data showed the presence of this mutation, but the variant caller Torrent Suite 2.0.1 failed to detect this mutation. This case was subsequently reanalyzed using our current variant calling pipeline (Torrent Suite 2.2), which correctly called the AKT1 mutation. The remaining two discrepancies both occurred secondary to a low mutant allele burden (5% and 3%), which was Excluding 13 mutations detected in genomic regions covered by only one of the two platforms, a total of three discrepancies were identified between NGS and PE-MALDI. The first discrepancy was an AKT1 p.E17K mutation (a custom amplicon added to the commercial AmpliSeq panel), which was detected at 24% allele burden by PE-MALDI but not by initial NGS analysis ( no significant differences. These findings suggest that the level of multiplexing in current panels has no effect on the ability to quantitate mutation burden. In addition, the read depth in the range of 728 to 9,958 did not seem to affect the quantitative ability of NGS. To our knowledge, ours is the first study to report these important correlates for using quantitative results for possible research and/or clinical purposes.
detected by NGS but was below the limit of detection of PE-MALDI (Table 2) . NGS-based mutation analysis involves a high level of multiplexing, as represented by the current panel, where 191 primer sets were included in a single PCR tube. To rule out a quantitative bias introduced by the level of multiplexing, we compared quantitative results from NGS and PE-MALDI with singleplex pyrosequencing and found correlated with percentage mutant allele burden for all five interrogated genes, in aggregate and individually. For these five genes, there was no statistically significant correlation between estimated tumor percentage and percent mutant allele burden as detected by either NGS or PE-MALDI. Such lack of a correlation is not entirely surprising. Factors such as tumor heterogeneity, copy number changes, and loss of heterozygosity (LOH), which affect the ratio of mutant A second aspect of estimating mutant allele burden by NGS that has not been thoroughly explored is its correlation with tumor percentage as estimated by pathologist review of H&E-stained tissue sections of tumor. Due to possible discrepancies that could arise based on review by a single pathologist, we used a three-pathologist consensus approach to improve our accuracy in estimating tumor percentage. The consensus tumor percentage was subsequently Our study documents for the first time a detailed assessment of the quantitative ability of NGS-based genotyping. In addition, NGS-based genotyping offers several advantages over standard qualitative measures, including a high level of multiplexing, nanogram amounts of starting material, rapid turnaround time, and the possibility of detecting secondary or co-mutations present in the presence or absence of the tested gene of interest. With increased adoption, the use of high-throughput NGS to quantify somatic mutations in solid tumors will rapidly advance our basic knowledge of tumor biology. Our results open up exciting possibilities for evaluating the clinical response to WT allele ratio, have been described and experimentally proven in solid tumors. [31] [32] [33] [34] Morphologic reevaluation of H&E-stained slides from cases that were discrepant with NGS or PE-MALDI results did not result in a change in the original estimate of tumor percentage and did not explain the discrepancies. This result suggests that biological factors could be primarily responsible for the observation. A potential but less likely and difficult-to-prove reason is possible differential extraction of DNA from tumor vs normal cells within the sample. Eventually, the determination of mutant allele burden needs to be used in conjunction with copy number changes and LOH studies. 
